Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Drugs Made In America Acquisition Cash-to-Debt?
Drugs Made In America AcquisitionDMAA 17 Cash-to-Debt is 0.02 as of Jun. 2026, which is 78% below its 10-year median of 0.09. GuruFocus rates DMAA with a GF Score™ of 17/100. The stock has 2 warning signs investors should review. Among 481 Diversified Financial Services companies, Drugs Made In America Acquisition ranks worse than 93.56% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Drugs Made In America Acquisition's cash to debt ratio for the quarter that ended in Jun. 2026 was 0.02.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Drugs Made In America Acquisitioncouldn't pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Drugs Made In America Acquisition's Cash-to-Debt or its related term are showing as below:
DMAA'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.09 Max: No Debt
Current: 0.02
During the past 2 years, Drugs Made In America Acquisition's highest Cash to Debt Ratio was No Debt. The lowest was 0.00. And the median was 0.09.
DMAA's Cash-to-Debt is ranked worse than 93.56% of 481
companies
in the Diversified Financial Services industry
Industry Median: 9.81
vs DMAA: 0.02
Drugs Made In America Acquisition (NAS:DMAA) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Drugs Made In America Acquisition Cash-to-Debt Related Terms
Drugs Made In America Acquisition Cash-to-Debt Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Drugs Made In America Acquisition Cash-to-Debt Chart
For the Shell Companies subindustry, Drugs Made In America Acquisition's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Drugs Made In America Acquisition Cash-to-Debt vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Drugs Made In America Acquisition's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Drugs Made In America Acquisition's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Drugs Made In America Acquisition (DMAA) has a Cash-to-Debt of 0.02 as of Jun. 2026. This is 78% below median its historical median of 0.09. According to the industry distribution chart, Drugs Made In America Acquisition ranks #450 out of 481 companies in the Diversified Financial Services industry, placing it in the top 93.6%.
Is Drugs Made In America Acquisition's Cash-to-Debt too high?
Drugs Made In America Acquisition's current Cash-to-Debt of 0.02 is 78% below median its 10-year median of 0.09. The Diversified Financial Services industry median Cash-to-Debt is 9.81. Drugs Made In America Acquisition's value of 0.02 is 99.8% below this industry median. Based on the distribution chart, Drugs Made In America Acquisition ranks #450 out of 481 companies in the Diversified Financial Services industry, which is in the bottom quartile relative to peers. Overall, Drugs Made In America Acquisition has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Drugs Made In America Acquisition's Cash-to-Debt compare to FACT and TRGS?
According to the Diversified Financial Services industry distribution chart, Drugs Made In America Acquisition ranks #450 out of 481 companies for Cash-to-Debt. This places Drugs Made In America Acquisition in the lower half of its industry. The industry median Cash-to-Debt is 9.81. Drugs Made In America Acquisition's value of 0.02 is 99.8% below this benchmark. While the company's 10-year median is 0.09 vs. the industry median of 9.81, Drugs Made In America Acquisition has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Diversified Financial Services company?
The median Cash-to-Debt among Diversified Financial Services companies is 9.81, based on 481 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Drugs Made In America Acquisition's current Cash-to-Debt of 0.02 is 99.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Diversified Financial Services industry, the median Cash-to-Debt is 9.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Drugs Made In America Acquisition's current Cash-to-Debt is 0.02, which is 78% below median its own 10-year median of 0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Drugs Made In America Acquisition stock overvalued right now?
Drugs Made In America Acquisition (DMAA) has a current Cash-to-Debt of 0.02. The current Cash-to-Debt is 0.02, which is 78% below median its 10-year median of 0.09 and 99.8% below the Diversified Financial Services industry median of 9.81. Drugs Made In America Acquisition's overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Drugs Made In America Acquisition (DMAA), the current Cash-to-Debt is 0.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DMAA has been successfully added to your 
